Route 92 Medical's Reperfusion System Shows Positive Outcomes in Trial

Session report ESOC 2025: Acute reperfusion treatment

.flex_column.av-pxfofs-f8cffa300d0abe60229a0238b37e998b{ border-radius:0px 0px 0px 0px; padding:0px 0px 0px 0px; } 22/05/2025/in ESO, ESOC, Stroke Research /by Stefania De Vito Session Report: Acute reperfusion treatment – exploring the margins Author: Christian Boehme, MD, PhD X: @chris7ianb In the evening of Day 1 at ESOC 2025 here in Helsinki, Finland, Götz Thomalla (Hamburg, Germany) and Bertrand Lapergue (Suresnes, France) chaired this firs…

Route 92 Medical's reperfusion system shows positive outcomes in trial

Route 92 Medical has announced that its HiPoint Reperfusion System has shown positive outcomes in the trial.The post Route 92 Medical’s reperfusion system shows positive outcomes in trial appeared first on Medical Device Network.

Route 92 HiPoint 88 Reperfusion System Cleared by FDA - Endovascular Today

May 21, 2025—Route 92 Medical, Inc. announced FDA 510(k) clearance (product code: NRY) for the company’s HiPoint reperfusion system, which includes the HiPoint 88 reperfusion system with the Tenzing 8 delivery catheter and featuring the Monopoint approach. Additionally, the company announced results from its pivotal SUMMIT MAX randomized controlled trial. The endovascular stroke thrombectomy study compared the efficacy and safety of the company’…